RxDoctor Payments DataLook up a doctor →

Kelly Nolin

Primary Care · Enfield, CTNPI 1033627872

Payments from drug & device makers

$16,456in general payments, 2019–2025

Across 884 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Pfizer$849
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$16,431100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,456 in reported general payments places this provider in the 95th percentile of 111 primary care providers in Connecticut.

See all primary care providers in Connecticut

Medicare billing

Part B allowed, 2024
$31,932
Medicare patients
117
Services billed
459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin143$162,302
Trelegy ElliptaFluticasone/Umeclidin/Vilanter100$94,507
OzempicSemaglutide69$88,115
EliquisApixaban86$81,271
MounjaroTirzepatide61$73,123
VraylarCariprazine Hcl33$49,120
Synjardy XrEmpagliflozin/Metformin Hcl28$48,569
FarxigaDapagliflozin Propanediol22$30,647
GlyxambiEmpagliflozin/Linagliptin70$27,522
RybelsusSemaglutide12$25,895
SublocadeBuprenorphine12$24,679
Nurtec OdtRimegepant Sulfate11$21,150
QuliptaAtogepant13$16,485
VascepaIcosapent Ethyl43$14,414
Breo ElliptaFluticasone/Vilanterol27$13,296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi$761$238,393241 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,159$117,327138 claims
Novo NordiskOzempic, Rybelsus$1,387$114,01081 claims
PfizerEliquis, Nurtec Odt$849$102,42197 claims
Lilly USA, LLCMounjaro, Trulicity$1,143$85,98272 claims
AbbVieVraylar, Qulipta, Synthroid$3,999$69,38278 claims
AstraZenecaFarxiga$1,257$30,64722 claims
Indivior Inc.Sublocade$138$24,67912 claims
Arbor Pharmaceuticals, Inc.Horizant$144$10,64211 claims
Eisai Inc.Dayvigo$42$5,64513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 primary care providers in Connecticut.

Other primary care in Enfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →